ADVFN US – Market Content Editor

Shares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) advanced 2.4% after the company announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (IND) application for RP-A701, a gene therapy aimed at treating BAG3-associated Dilated Cardiomyopathy (DCM). The regulatory green light represents a major development for Rocket’s pipeline of cardiovascular gene therapies. RP-A701…

Tempus AI (NASDAQ:TEM) shares declined 2.6% after the precision medicine technology firm revealed plans for a $400 million offering of convertible senior notes due in 2030. The Chicago-based company aims to use part of the proceeds to repay existing term loans, including immediately settling its $275 million 2027 term loan. This repayment is expected to…

Shares of Zscaler (NASDAQ:ZS) declined over 3% in premarket trading Monday after the cloud security company revealed plans to raise $1.5 billion by issuing convertible bonds with a three-year maturity. The firm intends to use part of the proceeds to purchase capped calls—financial instruments that help limit dilution risk when bonds convert to shares. The…

INmune Bio Inc. (NASDAQ:INMB) saw its stock plunge 60% in premarket trading Monday, following the release of mixed data from its Phase 2 MINDFuL trial evaluating XPro, a therapy aimed at treating early-stage Alzheimer’s disease. The biotech company, which specializes in immunological approaches to neurodegenerative conditions, disclosed that XPro did not achieve the primary endpoint…

Unicycive Therapeutics Inc (NASDAQ:UNCY) saw its shares plunge 26% in early trading after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the company’s application for Oxylanthanum Carbonate (OLC), a treatment for hyperphosphatemia in patients undergoing dialysis for chronic kidney disease. According to the company, the FDA’s rejection was not…

Palantir Technologies Inc (NASDAQ:PLTR) climbed 5% in premarket trading Monday, rebounding after a sharp 11% decline last Friday that was tied to technical market movements caused by FTSE Russell’s annual index reshuffling. The stock’s comeback was fueled not only by a general uplift in the tech sector—driven by renewed optimism over U.S. trade negotiations—but also…

Gilead Sciences (NASDAQ:GILD) continued to rally in early Monday trading, building on Friday’s 2.8% gain, following a significant U.S. Supreme Court decision that upheld a central piece of the Affordable Care Act (ACA). The ruling ensures that insurers must continue covering preventive healthcare services—such as HIV prevention medications and cancer screenings—without passing additional costs to…

Shares of major U.S. hospital operators came under pressure in premarket trading Monday, after a fresh analysis from Bank of America (BofA) suggested that the Senate’s newly revised reconciliation bill could pose greater financial risks to the sector than previously expected. The updated legislation, which passed the Senate on June 28, includes provisions that reintroduce…